Home Newsfeeds JP Morgan Downgrades Trinet Group to Underweight, Announces $96 Price Target

JP Morgan Downgrades Trinet Group to Underweight, Announces $96 Price Target

JP Morgan analyst Tien-Tsin Huang downgrades Trinet Group (NYSE:TNET) from Neutral to Underweight and announces $96 price target.

byBenzinga Newsdesk

August 16, 2022

1 minute read

JP Morgan analyst Tien-Tsin Huang downgrades Trinet Group (NYSE:TNET) from Neutral to Underweight and announces $96 price target.

AT&T, Merck And This Leading Payments Processor Stock On CNBC’s ‘Final Trades’

By Priya Nigam

December 28, 9:32 AM

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Visa Inc. (NYSE: V), which is down just 5% this year, and has high free cash flow yields

ETH

Benchmark Maintains Buy on The Middleby, Raises Price Target to $175

By Benzinga Newsdesk

February 22, 10:25 AM

Benchmark analyst Todd Brooks maintains The Middleby (NASDAQ:MIDD) with a Buy and raises the price target from $170 to $175.

MIDD

Analyst Ratings

Where Kala Pharmaceuticals Stands With Analysts

By Benzinga Insights

May 1, 2:00 PM

Within the last quarter, Kala Pharmaceuticals (NASDAQ:KALA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

KALA

UNITY Biotechnology’s Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron’s Drug

By Vandana Singh

March 27, 11:28 AM

UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

JP Morgan Downgrades Trinet Group to Underweight, Announces $96 Price Target

Related Posts

AT&T, Merck And This Leading Payments Processor Stock On CNBC’s ‘Final Trades’

Benchmark Maintains Buy on The Middleby, Raises Price Target to $175

Where Kala Pharmaceuticals Stands With Analysts

UNITY Biotechnology’s Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron’s Drug